Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction.
about
Caspases: pharmacological manipulation of cell deathAutocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosisTargeting Cell Survival Proteins for Cancer Cell DeathHarnessing the apoptotic programs in cancer stem-like cellsInteraction of a Cyclic, Bivalent Smac Mimetic with the X-Linked Inhibitor of Apoptosis Protein † ‡The structure of XIAP BIR2: understanding the selectivity of the BIR domainsAn unconventional IAP-binding motif revealed by target-assisted iterative screening (TAIS) of the BIR3-cIAP1 domain.Identification of small molecule inhibitors of cytokinesis and single cell wound repair.E3 ubiquitin ligases as cancer targets and biomarkers.Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.Apoptosis-based therapies and drug targets.Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeuticsDesign, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAPInhibitor of apoptosis proteins as targets for anticancer therapy.Hot-spot residues at the E9/Im9 interface help binding via different mechanisms.X-linked inhibitor of apoptosis protein as a therapeutic target.E9-Im9 colicin DNase-immunity protein biomolecular association in water: a multiple-copy and accelerated molecular dynamics simulation studyTargeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies.Design of small-molecule peptidic and nonpeptidic Smac mimetics.IAP-targeted therapies for cancer.Caspase-9 activation by the apoptosome is not required for fas-mediated apoptosis in type II Jurkat cells.Anti-cancer IAP antagonists promote bone metastasis: a cautionary tale.Apoptosis in leukemias: regulation and therapeutic targeting.Role of Bcl-2 family proteins and caspases in the regulation of apoptosis.Targeting inhibitor of apoptosis proteins for therapeutic intervention.Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.Immunohistochemical detection of XIAP in melanoma.Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors.XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs.Development of Peptidomimetics Targeting IAPsInhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.Cell-penetrating peptide-conjugated XIAP-inhibitory cyclic hexapeptides enter into Jurkat cells and inhibit cell proliferation.A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein.Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway.
P2860
Q24536096-68320A98-F4EA-4EB2-8845-F7FD57A71C40Q24609324-A7A6041F-821B-4B77-BF23-2AD3159EFCCCQ26765447-416DAB8C-278A-4D5F-A534-C03DE5B540F8Q26801037-D20F7292-67D5-49D6-803F-E4EADE374220Q27651733-0A13008A-7F37-418B-857B-8583A4895815Q27679855-D3146796-0448-4632-B3A3-333580CD4570Q33263114-366B079E-82DF-46C6-9503-7B0C6BAC25AEQ34466488-D998975B-C15D-44DB-941B-55CD31D05DE2Q35082710-E8F095A1-0C9F-4588-AEF8-3D6239EF4FCFQ35847722-501DA7F0-E132-4755-AD3A-8C950CD1E486Q36017772-554B7DE1-96E0-4D44-80F5-A0963B9AED74Q36274969-506D2230-381E-420D-8E14-F44AD0C57713Q36491838-C60954AF-A9B7-42DC-A236-F1CC5D520FBAQ36501732-B395D787-F0D6-453B-A719-08EA2C29039DQ36909606-A37E79F2-44E5-4805-A218-C5C402B6247BQ36950485-CC109600-FB82-427C-8CAF-170960A92899Q36953805-BE1F39DD-12C0-4773-A395-ABEA54CAD0A6Q37008849-CC8466B3-5856-4224-B724-029C56BC1FB3Q37118683-43E91137-BC94-4E14-9090-AD72FF0F1CB7Q37123892-9324DF44-B998-481E-8F35-75DFCC374803Q37176751-161C032F-4AE0-46AC-8264-227198F72355Q37302745-98D204E3-DA7E-4F08-873B-6A6CFA0E20B8Q37446194-D5AE2E7A-0C42-40D2-AB70-A585E3411D54Q37654710-18FB8F94-1153-446E-9021-12AFBCA171D8Q37715814-EBC60644-E58B-4216-AC80-25763FED2FD9Q37826384-A42B3315-0484-411C-AF3D-B0459B0856E6Q37855868-E3B85746-6268-4EA5-AFE6-81712E2F34C5Q37875078-0A7504DD-71FB-470B-94F3-3F45B0C2EBC8Q38252591-AF0ACA2B-7718-4CAA-92E1-D3C6AE33CF95Q38427860-1DA57B61-6E45-4AE5-B23F-083C153717BAQ39477486-B5FDD450-17DF-4D09-ABAD-189C10F1A18CQ39924324-50AD78E0-1A35-464C-AE1C-5434EE7B9876Q40470946-4D103EC6-32EB-4397-A612-9A765159AF86Q41911916-B0EE69B2-7C52-4CE5-94D4-02D0FADEDCF7Q42949488-6776E37F-F82D-40F6-B310-E61E0E712E72Q46240082-C7689CEC-DEF8-453A-8F1F-7F26B77AD832Q46806247-16DEBD2D-F18A-4A90-B9DC-82DA8714B2FBQ47128815-A9AA36D6-90C3-4FEC-BEBF-B251F2E13C56
P2860
Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Development and characterizati ...... he XIAP/caspase-3 interaction.
@ast
Development and characterizati ...... he XIAP/caspase-3 interaction.
@en
type
label
Development and characterizati ...... he XIAP/caspase-3 interaction.
@ast
Development and characterizati ...... he XIAP/caspase-3 interaction.
@en
prefLabel
Development and characterizati ...... he XIAP/caspase-3 interaction.
@ast
Development and characterizati ...... he XIAP/caspase-3 interaction.
@en
P2093
P1476
Development and characterizati ...... he XIAP/caspase-3 interaction.
@en
P2093
Badry Bursulaya
Klaus W Wagner
Peter G Schultz
Quinn L Deveraux
Tom Y H Wu
P304
P356
10.1016/S1074-5521(03)00157-1
P577
2003-08-01T00:00:00Z